<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">safetyrisk</journal-id><journal-title-group><journal-title xml:lang="ru">Безопасность и риск фармакотерапии</journal-title><trans-title-group xml:lang="en"><trans-title>Safety and Risk of Pharmacotherapy</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2312-7821</issn><issn pub-type="epub">2619-1164</issn><publisher><publisher-name>Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.30895/2312-7821-2026-14-1-33-43</article-id><article-id custom-type="elpub" pub-id-type="custom">safetyrisk-543</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ГЛАВНАЯ ТЕМА: ЭВОЛЮЦИЯ ФАРМАКОНАДЗОРА: ИНТЕГРАЦИЯ НОВЫХ ИСТОЧНИКОВ ДАННЫХ, ПОПУЛЯЦИОННЫХ ИCСЛЕДОВАНИЙ И ПРЕДИКТИВНЫХ ТЕХНОЛОГИЙ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>MAIN TOPIC: EVOLUTION OF PHARMACOVIGILANCE: INTEGRATING NEW DATA SOURCES,  POPULATION STUDIES AND PREDICTIVE TECHNOLOGIES</subject></subj-group></article-categories><title-group><article-title>Социальная сеть «ВКонтакте» как источник данных для фармаконадзора: возможность использования держателем регистрационного удостоверения</article-title><trans-title-group xml:lang="en"><trans-title>VKontakte Social Network as a Data Source for Pharmacovigilance: Applicability for Marketing Authorization Holders</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1508-0627</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Нежурина</surname><given-names>Е. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Nezhurina</surname><given-names>E. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Нежурина Елизавета Константиновна</p><p>Профсоюзная ул., д. 3, Москва, 117292</p></bio><bio xml:lang="en"><p>Elizaveta K. Nezhurina</p><p>3 Profsoyuznaya St., Moscow 117292</p></bio><email xlink:type="simple">elizaveta.nezhurina@lit-review.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4092-2539</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мильчаков</surname><given-names>К. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Milchakov</surname><given-names>K. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мильчаков Кирилл Сергеевич, канд. мед. наук, доцент</p><p>Профсоюзная ул., д. 3, Москва, 117292</p></bio><bio xml:lang="en"><p>Kirill S. Milchakov, Cand. Sci. (Med.), Associate Professor</p><p>3 Profsoyuznaya St., Moscow 117292</p></bio><email xlink:type="simple">info@lit-review.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-5739-4610</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Абрамова</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Abramova</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Абрамова Анна Андреевна</p><p>Профсоюзная ул., д. 3, Москва, 117292; ул. Миклухо-Маклая, д. 6, Москва, 117198</p></bio><bio xml:lang="en"><p>Anna A. Abramova</p><p>3 Profsoyuznaya St., Moscow 117292; 6 Miklukho-Maklay St., Moscow 117198</p></bio><email xlink:type="simple">anna.abramova@lit-review.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Научное медицинское агентство «Литобзор»<country>Россия</country></aff><aff xml:lang="en">LitReview Agency<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">Научное медицинское агентство «Литобзор»;&#13;
Федеральное государственное автономное образовательное учреждение высшего образования «Российский университет дружбы народов имени Патриса Лумумбы»<country>Россия</country></aff><aff xml:lang="en">LitReview Agency;&#13;
Рeoples’ Friendship University of Russia named after Patrice Lumumba<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>31</day><month>03</month><year>2026</year></pub-date><volume>14</volume><issue>1</issue><fpage>33</fpage><lpage>43</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Нежурина Е.К., Мильчаков К.С., Абрамова А.А., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Нежурина Е.К., Мильчаков К.С., Абрамова А.А.</copyright-holder><copyright-holder xml:lang="en">Nezhurina E.K., Milchakov K.S., Abramova A.A.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.risksafety.ru/jour/article/view/543">https://www.risksafety.ru/jour/article/view/543</self-uri><abstract><sec><title>ВВЕДЕНИЕ</title><p>ВВЕДЕНИЕ. Социальные медиа (социальные сети, форумы, сайты отзывов) могут содержать важную информацию о нежелательных реакциях при применении лекарственных препаратов. Исследования русскоязычных социальных медиа как источника информации для фармаконадзора в Российской Федерации ранее не проводились.</p></sec><sec><title>ЦЕЛЬ</title><p>ЦЕЛЬ. Оценить возможность использования российской социальной сети «ВКонтакте» как дополнительного источника сообщений о нежелательных реакциях на примере мониторинга упоминаний о применении метформина, азитромицина, метронидазола и клотримазола.</p></sec><sec><title>МАТЕРИАЛЫ И МЕТОДЫ</title><p>МАТЕРИАЛЫ И МЕТОДЫ. Проведен мониторинг социальной сети «ВКонтакте» в период с 01.09.2023 по 31.03.2024 при помощи программного обеспечения LITVISOR® для сбора пользовательских сообщений, содержащих упоминания о применении лекарственных препаратов с международными непатентованными наименованиями метформин, азитромицин, метронидазол, клотримазол. Оценивали полноту информации о репортере и пациенте в сообщениях, выявляли нежелательные реакции и особые ситуации по безопасности. Полученную информацию по безопасности кодировали в соответствии с терминологией MedDRA, оценивали серьезность и предвиденность нежелательных реакций.</p></sec><sec><title>РЕЗУЛЬТАТЫ</title><p>РЕЗУЛЬТАТЫ. Мониторинг социальной сети «ВКонтакте» позволил обнаружить 4969 записей о случаях применения азитромицина, метформина, метронидазола и клотримазола. В 124 (2,5%) сообщениях выявлена информация о 195 нежелательных реакциях, которые были отнесены к 15 системно-органным классам. Как несерьезные были квалифицированы 93,3% случаев, как серьезные — 6,7%. Предвиденными были 85,6% нежелательных реакций, непредвиденными — 14,4%. Выявлены случаи off-label применения лекарственных препаратов, передозировки, применения у беременных женщин. В 35,5% спонтанных сообщений репортер был идентифицирован, в 89,5% был известен пол пациента, в 36,3% — возраст пациента.</p></sec><sec><title>ВЫВОДЫ</title><p>ВЫВОДЫ. В исследовании показано, что мониторинг русскоязычной социальной сети «ВКонтакте» перспективен для получения данных по безопасности лекарственных препаратов, разрешенных к применению в Российской Федерации. Подтверждена принципиальная возможность валидации записей пользователей социальной сети как спонтанных сообщений.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title> </title><p> </p></sec><sec><title>INTRODUCTION</title><p>INTRODUCTION. Social media (social networks, forums, review websites, etc.) contain a lot of essential information about adverse drug reactions (ADRs). So far, no previous studies of social media were conducted in the Russian Federation.</p></sec><sec><title>AIM</title><p>AIM. This study aimed to evaluate the possibility of using VKontakte social network as an additional source of ADR reports exemplified by users mentioning the use of metformin, azithromycin, metronidazole, and clotrimazole.</p></sec><sec><title>MATERIALS AND METHODS</title><p>MATERIALS AND METHODS. VKontakte social network was monitored for the period of 09.01.2023 to 03.31.2024 using LITVISOR® software to collect entries mentioning the use of metformin, azithromycin, metronidazole, and clotrimazole (International Non-proprietary Names). We analyzed the completeness of information about the reporters and the patients, as well as ADRs and special safety situations. The identified safety information was encoded using MedDRA terminology; their seriousness and listedness were assessed.</p></sec><sec><title>RESULTS</title><p>RESULTS. A monitoring of VKontakte social network resulted in 4,969 entries on the use of azithromycin, metformin, metronidazole, and clotrimazole. We identified 195 ADRs related to 15 systemic organ classes; of them, 93.3% were classified as non-serious and 6.7% as serious. 85.56% of ADRs were expected, while 14.4% were unexpected. Cases of off-label use, overdose, and use in pregnant women were identified. In 35.5% of spontaneous reports, the reporter was identified, in 89.5%, the patient’s sex was known, and in 36.3%, the patient’s age was known.</p></sec><sec><title>CONCLUSIONS</title><p>CONCLUSIONS. The findings show that the monitoring of VKontakte social network is a promising source of data on drug safety approved in the Russian Federation. The study confirms the fundamental possibility of validating the entries from the social network users as spontaneous reports.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>мониторинг</kwd><kwd>фармаконадзор</kwd><kwd>социальные сети</kwd><kwd>социальные медиа</kwd><kwd>спонтанные сообщения</kwd><kwd>нежелательные реакции</kwd><kwd>метформин</kwd><kwd>азитромицин</kwd><kwd>метронидазол</kwd><kwd>клотримазол</kwd><kwd>безопасность лекарственных средств</kwd><kwd>данные реальной клинической практики</kwd></kwd-group><kwd-group xml:lang="en"><kwd>pharmacovigilance</kwd><kwd>social media</kwd><kwd>social network</kwd><kwd>spontaneous report</kwd><kwd>adverse drug reaction</kwd><kwd>metformin</kwd><kwd>azithromycin</kwd><kwd>metronidazole</kwd><kwd>clotrimazole</kwd><kwd>drug safety</kwd><kwd>real-world data</kwd><kwd>RWD</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">van Stekelenborg J, Ellenius J, Maskell S, et al. Recommendations for the use of social media in pharmacovigilance: Lessons from IMI WEB-RADR. Drug Saf. 2019;42(12):1393–407. https://doi.org/10.1007/s40264-019-00858-7</mixed-citation><mixed-citation xml:lang="en">van Stekelenborg J, Ellenius J, Maskell S, et al. Recommendations for the use of social media in pharmacovigilance: Lessons from IMI WEB-RADR. Drug Saf. 2019;42(12):1393–407. https://doi.org/10.1007/s40264-019-00858-7</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Dietrich J, Gattepaille LM, Grum BA, et al. Adverse events in twitter-development of a benchmark reference dataset: Results from IMI WEB-RADR. Drug Saf. 2020;43(5):467–78. https://doi.org/10.1007/s40264-020-00912-9</mixed-citation><mixed-citation xml:lang="en">Dietrich J, Gattepaille LM, Grum BA, et al. Adverse events in twitter-development of a benchmark reference dataset: Results from IMI WEB-RADR. Drug Saf. 2020;43(5):467–78. https://doi.org/10.1007/s40264-020-00912-9</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Pierce CE, Bouri K, Pamer C, et al. Evaluation of Facebook and Twitter monitoring to detect safety signals for medical products: an analysis of recent FDA safety alerts. Drug Saf. 2017;40(4):317–31. https://doi.org/10.1007/s40264-016-0491-0</mixed-citation><mixed-citation xml:lang="en">Pierce CE, Bouri K, Pamer C, et al. Evaluation of Facebook and Twitter monitoring to detect safety signals for medical products: An analysis of recent FDA safety alerts. Drug Saf. 2017;40(4):317–31. https://doi.org/10.1007/s40264-016-0491-0</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Audeh B, Bellet F, Beyens MN, et al. Use of social media for pharmacovigilance activities: Key findings and recommendations from the Vigi4Med Project. Drug Saf. 2020;43(9):835–51. https://doi.org/10.1007/s40264-020-00951-2</mixed-citation><mixed-citation xml:lang="en">Audeh B, Bellet F, Beyens MN, et al. Use of social media for pharmacovigilance activities: Key findings and recommendations from the Vigi4Med Project. Drug Saf. 2020;43(9):835–51. https://doi.org/10.1007/s40264-020-00951-2</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Karapetiantz P, Bellet F, Audeh B, et al. Descriptions of adverse drug reactions are less informative in forums than in the French Pharmacovigilance Database but provide more unexpected reactions. Front Pharmacol. 2018;9:439. https://doi.org/10.3389/fphar.2018.00439</mixed-citation><mixed-citation xml:lang="en">Karapetiantz P, Bellet F, Audeh B, et al. Descriptions of adverse drug reactions are less informative in forums than in the French Pharmacovigilance Database but provide more unexpected reactions. Front Pharmacol. 2018;9:439. https://doi.org/10.3389/fphar.2018.00439</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Gattepaille LM, Hedfors Vidlin S, Bergvall T, et al. Prospective evaluation of adverse event recognition systems in Twitter: Results from the Web-RADR Project. Drug Saf. 2020;43(8):797–808. https://doi.org/10.1007/s40264-020-00942-3</mixed-citation><mixed-citation xml:lang="en">Gattepaille LM, Hedfors Vidlin S, Bergvall T, et al. Prospective evaluation of adverse event recognition systems in Twitter: Results from the Web-RADR Project. Drug Saf. 2020;43(8):797–808. https://doi.org/10.1007/s40264-020-00942-3</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Schück S, Roustamal A, Gedik A, et al. Assessing patient perceptions and experiences of paracetamol in France: Infodemiology study using social media data mining. J Med Internet Res. 2021;23(7):e25049. https://doi.org/10.2196/25049</mixed-citation><mixed-citation xml:lang="en">Schück S, Roustamal A, Gedik A, et al. Assessing patient perceptions and experiences of paracetamol in France: Infodemiology study using social media data mining. J Med Internet Res. 2021;23(7):e25049.https://doi.org/10.2196/25049</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Natter J, Michel B. Memantine misuse and social networks: A content analysis of Internet self-reports. Pharmacoepidemiol Drug Saf. 2020;29(9):1189–93. https://doi.org/10.1002/pds.5070</mixed-citation><mixed-citation xml:lang="en">Natter J, Michel B. Memantine misuse and social networks: A content analysis of Internet self-reports. Pharmacoepidemiol Drug Saf. 2020;29(9):1189–93. https://doi.org/10.1002/pds.5070</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Rezaallah B, Lewis DJ, Pierce C, et al. Social media surveillance of multiple sclerosis medications used during pregnancy and breastfeeding: Content analysis. J Med Internet Res. 2019;21(8):e13003. https://doi.org/10.2196/13003</mixed-citation><mixed-citation xml:lang="en">Rezaallah B, Lewis DJ, Pierce C, et al. Social media surveillance of multiple sclerosis medications used during pregnancy and breastfeeding: Content analysis. J Med Internet Res. 2019;21(8):e13003. https://doi.org/10.2196/13003</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Golder S, Chiuve S, Weissenbacher D, et al. Pharmacoepidemiologic evaluation of birth defects from health-related postings in social media during pregnancy. Drug Saf. 2019;42(3):389–400. https://doi.org/10.1007/s40264-018-0731-6</mixed-citation><mixed-citation xml:lang="en">Golder S, Chiuve S, Weissenbacher D, et al. Pharmacoepidemiologic evaluation of birth defects from health-related postings in social media during pregnancy. Drug Saf. 2019;42(3):389–400. https://doi.org/10.1007/s40264-018-0731-6</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Khashei M, Janiczak S, St Clair C, et al. Social media for early characterization of pandemic symptoms: A qualitative analysis of patient-reported COVID-19 experiences. Pharmacoepidemiol Drug Saf. 2023;32(3):341–351. https://doi.org/10.1002/pds.5564</mixed-citation><mixed-citation xml:lang="en">Khashei M, Janiczak S, St Clair C, et al. Social media for early characterization of pandemic symptoms: A qualitative analysis of patient-reported COVID-19 experiences. Pharmacoepidemiol Drug Saf. 2023;32(3):341–351. https://doi.org/10.1002/pds.5564</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Tutubalina E, Alimova I, Miftahutdinov Z, et al. The Russian drug reaction corpus and neural models for drug reactions and effectiveness detection in user reviews. Bioinformatics. 2021;37(2):243–9. https://doi.org/10.1093/bioinformatics/btaa675</mixed-citation><mixed-citation xml:lang="en">Tutubalina E, Alimova I, Miftahutdinov Z, et al. The Russian drug reaction corpus and neural models for drug reactions and effectiveness detection in user reviews. Bioinformatics. 2021;37(2):243–9. https://doi.org/10.1093/bioinformatics/btaa675</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Буралкина НА, Шабалова ОВ. Вульвовагинальный кандидоз: этиология, патогенез, диагностика, лечение. Медицинский Совет. 2019;(12):142–5. https://doi.org/10.21518/2079-701X-2019-12-142-145</mixed-citation><mixed-citation xml:lang="en">Buralkina NA, Shabalova OV. Vulvovaginal candidiasis: Etiology, pathogenesis, diagnosis, treatment. Medical Council. 2019;(12):142–5 (In Russ.). https://doi.org/10.21518/2079-701X-2019-12-142-145</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Sadah SA, Shahbazi M, Wiley MT, Hristidis V. Demographic-based content analysis of web-based health-related social media. J Med Internet Res. 2016;18(6):e148. https://doi.org/10.2196/jmir.5327</mixed-citation><mixed-citation xml:lang="en">Sadah SA, Shahbazi M, Wiley MT, Hristidis V. Demographic-based content analysis of web-based health-related social media. J Med Internet Res. 2016;18(6):e148. https://doi.org/10.2196/jmir.5327</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Скрябина АА, Никифоров ВВ, Шахмарданов МЗ и др. Нежелательные реакции, возникающие на фоне терапии макролидами: анализ спонтанных сообщений по данным подсистемы «Фармаконадзор». Клиническая микробиология и антимикробная химиотерапия. 2023;25(1):34–40. https://doi.org/10.36488/cmac.2023.1.34-40</mixed-citation><mixed-citation xml:lang="en">Skryabina AA, Nikiforov VV, Shakhmardanov MZ, et al. Adverse drug reactions of macrolide therapy: analysis of spontaneous reports according to the pharmacovigilance system. Clinical Microbiology and Antimicrobial Therapy. 2023;25(1):34–40 (In Russ.). https://doi.org/10.36488/cmac.2023.1.34-40</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Hansen MP, Scott AM, McCullough A, et al. Adverse events in people taking macrolide antibiotics versus placebo for any indication. Cochrane Database Syst Rev. 2019;1(1):CD011825. https://doi.org/10.1002/14651858.CD011825.pub2</mixed-citation><mixed-citation xml:lang="en">Hansen MP, Scott AM, McCullough A, et al. Adverse events in people taking macrolide antibiotics versus placebo for any indication. Cochrane Database Syst Rev. 2019;1(1):CD011825. https://doi.org/10.1002/14651858.CD011825.pub2</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
